Other and unspecified diseases of blood and blood-forming organs
Notes: Benign polycythemia ; Familial polycythemia ; Acquired polycythemia ; Emotional polycythemia ; Erythrocytosis NOS ; Hypoxemic polycythemia ; Nephrogenous polycythemia ; Polycythemia due to erythropoietin ; Polycythemia due to fall in plasma volume ; Polycythemia due to high altitude ; Polycythemia due to stress ; Polycythemia NOS ; Relative polycythemia ; Myelofibrosis NOS ; Secondary myelofibrosis NOS ; Non-immune HIT ; Type 1 heparin-induced thrombocytopenia ; Immune-mediated HIT ; Type 2 heparin-induced thrombocytopenia ; Autoimmune heparin-induced thrombocytopenia syndrome ; Delayed-onset heparin-induced thrombocytopenia ; Persisting heparin-induced thrombocytopenia ; Reactive thrombocytosis ; Secondary thrombocytosis ; Thrombocythemia NOS ; Thrombocytosis NOS ; Spontaneous heparin-induced thrombocytopenia syndrome (without heparin exposure) ; Thrombosis with thrombocytopenia syndrome ; Vaccine-induced thrombotic thrombocytopenia ; code, if applicable, for associated therapy-related myelodysplastic syndrome (D46.-) ; code for adverse effect, if applicable, to identify drug (T45.1X5) ; code, if applicable, for adverse effect of heparin (T45.515-) ; code, if applicable, for adverse effect of other viral vaccine (T50.B95-) ; hereditary ovalocytosis (D58.1) ; polycythemia neonatorum (P61.1) ; polycythemia vera (D45) ; acute myelofibrosis (C94.4-) ; idiopathic myelofibrosis (D47.1) ; leukoerythroblastic anemia (D61.82) ; myelofibrosis with myeloid metaplasia (D47.4) ; myelophthisic anemia (D61.82) ; myelophthisis (D61.82) ; primary myelofibrosis (D47.1) ; glucose-6-phosphate dehydrogenase (G6PD) deficiency with anemia (D55.0) ; acute lymphadenitis (L04.-) ; chronic lymphadenitis (I88.1) ; enlarged lymph nodes (R59.-) ; hypergammaglobulinemia NOS (D89.2) ; lymphadenitis NOS (I88.9) ; mesenteric lymphadenitis (acute) (chronic) (I88.0) ; essential thrombocythemia (D47.3) ; the underlying disorder, such as: ; malignant neoplasm of breast (C50.-)